Do analysts rate TLSA or SGMO?

Sangamo Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 13,413.51%. Given Sangamo Therapeutics' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sangamo Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings & valuation, TLSA or SGMO?

Tiziana Life Sciences has higher earnings, but lower revenue than Sangamo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Sangamo Therapeutics $39.55M 0.78 -$122.93M -$0.38 N/A

Sangamo Therapeutics (SGMO) Competitors

$0.07 0.00 (0.00%)

As of 11/6/2026

Compare

SGMO vs. NGEN, TLSA, AVXL, VYGR, and ANIX

Should you buy Sangamo Therapeutics stock or one of its competitors? Sangamo Therapeutics's main competitors and comparable companies include NervGen Pharma (NGEN), Tiziana Life Sciences (TLSA), Anavex Life Sciences (AVXL), Voyager Therapeutics (VYGR), and Anixa Biosciences (ANIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, NervGen Pharma had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for NervGen Pharma and 0 mentions for Sangamo Therapeutics. NervGen Pharma's average media sentiment score of 0.61 beat Sangamo Therapeutics' score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
NervGen Pharma	Positive
Sangamo Therapeutics	Neutral

56.9% of Sangamo Therapeutics shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NervGen Pharma has higher earnings, but lower revenue than Sangamo Therapeutics. NervGen Pharma is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.64M	-$0.46	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

NervGen Pharma presently has a consensus price target of $14.00, indicating a potential upside of 743.88%. Sangamo Therapeutics has a consensus price target of $10.00, indicating a potential upside of 13,413.51%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than NervGen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Sangamo Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

NervGen Pharma has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. NervGen Pharma's return on equity of -532.62% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-532.62%	-200.05%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Summary

NervGen Pharma beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

56.9% of Sangamo Therapeutics shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tiziana Life Sciences has higher earnings, but lower revenue than Sangamo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Tiziana Life Sciences has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Tiziana Life Sciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Tiziana Life Sciences' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Sangamo Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 13,413.51%. Given Sangamo Therapeutics' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sangamo Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Tiziana Life Sciences had 10 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 10 mentions for Tiziana Life Sciences and 0 mentions for Sangamo Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.49 beat Sangamo Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
Sangamo Therapeutics	Neutral

Summary

Tiziana Life Sciences beats Sangamo Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Anavex Life Sciences?

Sangamo Therapeutics (NASDAQ:SGMO) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sangamo Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 13,413.51%. Anavex Life Sciences has a consensus price target of $21.33, suggesting a potential upside of 2,061.43%. Given Sangamo Therapeutics' higher probable upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Anavex Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Anavex Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Anavex Life Sciences has lower revenue, but higher earnings than Sangamo Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A

Anavex Life Sciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Anavex Life Sciences' return on equity of -11.43% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Anavex Life Sciences	N/A	-11.43%	-10.72%

In the previous week, Anavex Life Sciences had 18 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 18 mentions for Anavex Life Sciences and 0 mentions for Sangamo Therapeutics. Anavex Life Sciences' average media sentiment score of 0.09 beat Sangamo Therapeutics' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Anavex Life Sciences	Neutral

Summary

Anavex Life Sciences beats Sangamo Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Voyager Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Sangamo Therapeutics has a net margin of -310.81% compared to Voyager Therapeutics' net margin of -416.32%. Voyager Therapeutics' return on equity of -63.42% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Voyager Therapeutics	-416.32%	-63.42%	-49.40%

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Voyager Therapeutics has higher revenue and earnings than Sangamo Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Voyager Therapeutics	$40.37M	2.45	-$119.72M	-$1.73	N/A

In the previous week, Voyager Therapeutics had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Voyager Therapeutics and 0 mentions for Sangamo Therapeutics. Voyager Therapeutics' average media sentiment score of 0.66 beat Sangamo Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Voyager Therapeutics	Positive

Sangamo Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 13,413.51%. Voyager Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,471.34%. Given Sangamo Therapeutics' higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Voyager Therapeutics beats Sangamo Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Anixa Biosciences?

Sangamo Therapeutics (NASDAQ:SGMO) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Sangamo Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 13,413.51%. Anixa Biosciences has a consensus price target of $8.00, indicating a potential upside of 195.20%. Given Sangamo Therapeutics' higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anixa Biosciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Anixa Biosciences' return on equity of -76.59% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Anixa Biosciences	N/A	-76.59%	-67.80%

In the previous week, Anixa Biosciences had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for Sangamo Therapeutics. Anixa Biosciences' average media sentiment score of 1.16 beat Sangamo Therapeutics' score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Anixa Biosciences	Positive

Anixa Biosciences has lower revenue, but higher earnings than Sangamo Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.32	N/A

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

Anixa Biosciences beats Sangamo Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.66M	$4.08B	$7.83B	$12.01B
Dividend Yield	N/A	3.62%	2.46%	4.50%
P/E Ratio	-0.17	24.52	34.41	30.36
Price / Sales	0.78	16.83	8.86	5.82
Price / Cash	N/A	26.89	22.23	22.80
Price / Book	-1.85	4.13	4.39	3.77
Net Income	-$122.93M	-$22.78M	$3.51B	$390.55M
7 Day Performance	N/A	-2.84%	-1.68%	-0.58%
1 Month Performance	N/A	-5.81%	-4.09%	-6.84%
1 Year Performance	N/A	-0.42%	0.66%	-6.12%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	0.7424 of 5 stars	$0.07 flat	$10.00 +13,413.5%	N/A	$30.66M	$39.55M	N/A	480
NGEN NervGen Pharma	1.9031 of 5 stars	$1.35 -1.5%	$14.00 +937.0%	N/A	$120.95M	N/A	N/A	8	News Coverage Gap Up
TLSA Tiziana Life Sciences	0.5112 of 5 stars	$0.67 -16.3%	N/A	-65.7%	$120.90M	N/A	N/A	10	High Trading Volume
AVXL Anavex Life Sciences	2.155 of 5 stars	$1.14 -4.2%	$21.33 +1,771.3%	-85.7%	$120.51M	N/A	N/A	34
VYGR Voyager Therapeutics	2.9441 of 5 stars	$1.78 +3.5%	$16.50 +827.0%	-60.0%	$113.38M	$40.37M	N/A	141

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. NGEN, TLSA, AVXL, VYGR, and ANIX

How does Sangamo Therapeutics compare to NervGen Pharma?

Summary

How does Sangamo Therapeutics compare to Tiziana Life Sciences?

Summary

How does Sangamo Therapeutics compare to Anavex Life Sciences?

Summary

How does Sangamo Therapeutics compare to Voyager Therapeutics?

Summary

How does Sangamo Therapeutics compare to Anixa Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. NGEN, TLSA, AVXL, VYGR, and ANIX

How does Sangamo Therapeutics compare to NervGen Pharma?

Does the media favor NGEN or SGMO?

Do insiders & institutionals have more ownership in NGEN or SGMO?

Which has stronger valuation & earnings, NGEN or SGMO?

Do analysts recommend NGEN or SGMO?

Is NGEN or SGMO more profitable?

Summary

How does Sangamo Therapeutics compare to Tiziana Life Sciences?

Do insiders and institutionals hold more shares of TLSA or SGMO?

Which has higher earnings & valuation, TLSA or SGMO?

Which has more volatility & risk, TLSA or SGMO?

Is TLSA or SGMO more profitable?

Do analysts rate TLSA or SGMO?

Does the media favor TLSA or SGMO?

Summary

How does Sangamo Therapeutics compare to Anavex Life Sciences?

Do institutionals & insiders believe in SGMO or AVXL?

Do analysts rate SGMO or AVXL?

Which has more risk and volatility, SGMO or AVXL?

Which has better earnings and valuation, SGMO or AVXL?

Is SGMO or AVXL more profitable?

Does the media prefer SGMO or AVXL?

Summary

How does Sangamo Therapeutics compare to Voyager Therapeutics?

Is SGMO or VYGR more profitable?

Do institutionals & insiders have more ownership in SGMO or VYGR?

Which has more volatility and risk, SGMO or VYGR?

Which has higher valuation & earnings, SGMO or VYGR?

Does the media prefer SGMO or VYGR?

Do analysts rate SGMO or VYGR?

Summary

How does Sangamo Therapeutics compare to Anixa Biosciences?

Do analysts rate SGMO or ANIX?

Is SGMO or ANIX more profitable?

Does the media prefer SGMO or ANIX?

Which has higher valuation & earnings, SGMO or ANIX?

Do institutionals & insiders have more ownership in SGMO or ANIX?

Which has more volatility and risk, SGMO or ANIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools